ArticleTranslational lung cancer research2026
Promising benefits of MET inhibition combined with EGFR/ALK tyrosine kinase inhibitor in heavily treated non-small cell lung cancer patients with
Qianxin Zhou et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.